CERo Therapeutics (CERO) announces that TriStar Centennial Medical Center, through Sarah Cannon Research Institute, SCRI, in Nashville, Tennessee, is a clinical trial site for the Company’s Phase 1 clinical of CER-1236. Collaborating with SCRI to advance cancer research, TriStar Centennial offers innovative clinical research trials for various disease indications. The trial is focused on patients with acute myeloid leukemia, AML, and patient enrollment is underway, with expected dosing of the first patient during the first half of 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CERO:
- CERo Therapeutics Files Series D Stock Designations
- Cero Therapeutics to present on CER-1236 at ASCO meeting
- Cero Therapeutics announces SCRI at CBCI as key trial site for Phase 1 trial
- Cero Therapeutics enters securities purchase agreement for up to $8M
- Cero Therapeutics initiated with a Buy at D. Boral Capital